- Conditions
- Hepatic Impairment
- Interventions
- LY3314814
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 4
- States / cities
- Tustin, California • Miami, Florida • Orlando, Florida + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 1,902
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Urothelial Cancer
- Interventions
- MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, Gemcitabine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Stanford, California • Aurora, Colorado + 12 more
- Conditions
- Melanoma Neoplasms
- Interventions
- KU-0059436 (AZD2281)(PARP inhibitor), dacarbazine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Domvanalimab, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 791 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 28 more
- Conditions
- Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
- Interventions
- Ciclesonide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 41
- States / cities
- Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide - Exenatide - Placebo, Exenatide - Placebo - Exenatide, Placebo - Exenatide - Exenatide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 16 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • San Diego, California • Denver, Colorado + 2 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- AZD1208
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Houston, Texas
- Conditions
- Healthy Participants
- Interventions
- AZD5148, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Anniston, Alabama • Glendale, California • Baltimore, Maryland + 1 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg, Tiotropium 18 μg (TIO 18 μg), Placebo to TIO 18 μg
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 1,595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 85
- States / cities
- Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
- Conditions
- Healthy Volunteer
- Interventions
- celecoxib
- Drug
- Lead sponsor
- POZEN
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Healthy Japanese Volunteers
- Interventions
- Fostamatinib 100mg, Fostamatinib 200mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 20 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Relative Bioavailability, AUC, Cmax, Pharmacokinetics
- Interventions
- D1400147, D14000136, D14000137, Epanova®
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 137 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- Pramlintide acetate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002
- U.S. locations
- 4
- States / cities
- Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 1 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Durvalumab, Stereotactic Body Radiation Therapy (SBRT), Standard of Care Therapy
- Drug · Radiation · Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado
- Conditions
- Neurofibromatosis 2, Meningioma
- Interventions
- AZD2014
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Cardiovascular Disease
- Interventions
- AZD0780, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 357
- States / cities
- Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 284 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- non-interventional
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Not listed
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Redwood Shores, California
- Conditions
- Pulmonary Disease, Chronic Obstructive, Retrospective Studies
- Interventions
- BGF
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Healthy Participants, Dyslipidemia
- Interventions
- AZD4954, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL
- Interventions
- AZD3470, Pembrolizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 7
- States / cities
- Duarte, California • Miami, Florida • Atlanta, Georgia + 4 more
- Conditions
- Heterozygous Familial Hypercholesterolaemia
- Interventions
- AZD0780, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Garden Grove, California • San Diego, California • Miami Lakes, Florida + 16 more
- Conditions
- Advanced Cancer, Metastatic Cancer
- Interventions
- T-DXd
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Miami, Florida • Durham, North Carolina
- Conditions
- Asymptomatic Hyperuricemia
- Interventions
- Verinurad, Febuxostat, Dapagliflozin, Dapagliflozin matched placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Hepatobiliary Cancers
- Interventions
- Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more